Pharmaceuticals News

ROCKVILLE, Md. and SUZHOU, China, April 19, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company...

STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO-227 show...

WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments...

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma OS benefit observed across key subgroups, including patients with...

Company announcement – No. 8 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...

Company announcement – No. 7 / 2026 Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2026 Copenhagen, Denmark,...

REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with...

EDMONTON, Alberta , April 19, 2026 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc., a leader in the development of drugs to treat antibiotic-resistant infections, is presenting a full suite of...

Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months  Data highlighted in oral presentation at AACR’s Clinical...

- Los análisis de la respuesta tumoral, los biomarcadores y los subgrupos del ensayo clínico VIRAGE de Fase 2b respaldan el mecanismo de acción inmunomediado de VCN-01 y demuestran una mejora en los...